Researchers have developed a new opioid drug, UMB 425, which is as strong as morphine, but has reduced tolerance over time and no obvious toxic effects. The drug acts on two different opioid receptors in the body. The team plans to continue testing with the goal of developing two compounds derived form UMB 425 that would lead to Phase I clinical trials. Read more and access the study abstract.
© 2022 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder.